Company intelligence / Profile preview

Advanced Ophthalmic Innovations

Singapore, Singaporeaoi.sg ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead product, the PAUL® Glaucoma Implant, has been approved and used by leading ophthalmologists globally. It offers innovative design features for improved safety and efficacy in controlling intraocular pressure for glaucoma patients. Clinical adoption and regulatory approvals indicate strong performance and acceptance.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically glaucoma drainage device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

PAUL

Commercial

Indications: Glaucoma

Partnerships

Aequus Pharmaceuticals Inc. (exclusive distribution agreement for Canada)

Beyond the preview

Go deeper on Advanced Ophthalmic Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Ophthalmic Innovations.

Explore the full profile